Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetBio-CRC
This prospective clinical observational study aims to construct a metabolite database specifically for colorectal cancer patients using metabolomics technology. It seeks to develop and validate metabolic biomarkers for early diagnosis, prognosis, and prediction of recurrence and metastasis in colorectal cancer, thereby a establishing safe, convenient, and highly sensitive method for early screening and prognostic prediction.
• \*\*Healthy Controls:\*\*
∙ Age ≥ 18 years;
‣ Signed informed consent and willingness to participate in the project.
• \*\*Colorectal Cancer:\*\*
⁃ Age ≥ 18 years;
⁃ Performance status (ECOG) score ≤ 1;
⁃ Histopathologically confirmed colorectal adenocarcinoma;
⁃ No family history of hereditary cancer;
⁃ No prior anti-tumor treatment;
⁃ Availability of primary tumor tissue from surgery or biopsy that meets submission requirements;
⁃ Availability of peripheral blood samples that meet submission requirements;
⁃ Willingness and ability to sign the informed consent form to participate in the study.